{
  "id": 16889467,
  "title": "Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes",
  "url": "https://urgent.news/2026/10/28/lillys-triple-g-drug-retatrutide-outshines-novos-ozempic-in-diabetes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T10:45:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/lillys-triple-g-drug-retatrutide-outshines-novos-ozempic-in-diabetes/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabetes rather than obesity. The drug ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Eli Lilly reports promising lung cancer drug results",
        "url": "https://urgent.news/2026/10/25/eli-lilly-reports-promising-lung-cancer-drug-results",
        "published": "2026-10-25T22:57:44.000Z"
      },
      {
        "outlet": "BioPharma Dive",
        "title": "Court rejects Novo bid to block Lilly obesity drug ads",
        "url": "https://urgent.news/2026/10/27/court-rejects-novo-bid-to-block-lilly-obesity-drug-ads",
        "published": "2026-10-27T16:03:00.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more",
        "url": "https://urgent.news/2026/10/28/stat-pharmalittle-were-reading-about-340b-battles-new-results-for-a",
        "published": "2026-10-28T13:44:59.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}